Overcoming 3 Key Challenges Facing Life Science Contract Manufacturers

It has become clear that digitizing production processes is no longer optional for CMOs and CDMO's, but a necessity to keep up with the competition in the pharmaceutical, biotechnology, and medical technology industries. Research in 2022 projected the global pharmaceutical contract manufacturing market to reach $130 billion by 2026, the medical device contract manufacturing market to reach over $122 billion by 2027, and the biopharmaceutical contract manufacturing market to reach nearly $28 billion by 2028. A manual process will hinder organizations trying to manage that demand. In order to successfully implement a fully digitized production process, there are three key challenges that CMOs and CDMO's must overcome.

1. Production Inefficiencies Caused By Manual Processes
2. A Slow Pace When Adapting Due to Inflexible Systems
3. Poor Visibility Resulting From Disconnected Data Sources

Master Control offers modern manufacturing solutions to organizations that enable the removal of all paper from the production processes along with increased flexible and responsiveness when scaling up.